JPWO2020021097A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020021097A5 JPWO2020021097A5 JP2021504186A JP2021504186A JPWO2020021097A5 JP WO2020021097 A5 JPWO2020021097 A5 JP WO2020021097A5 JP 2021504186 A JP2021504186 A JP 2021504186A JP 2021504186 A JP2021504186 A JP 2021504186A JP WO2020021097 A5 JPWO2020021097 A5 JP WO2020021097A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- halogen
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024068208A JP2024096989A (ja) | 2018-07-26 | 2024-04-19 | 腎障害の処置で使用するための化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185871.3 | 2018-07-26 | ||
| EP18185871 | 2018-07-26 | ||
| PCT/EP2019/070251 WO2020021097A1 (en) | 2018-07-26 | 2019-07-26 | Compounds for use in treating kidney disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068208A Division JP2024096989A (ja) | 2018-07-26 | 2024-04-19 | 腎障害の処置で使用するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531308A JP2021531308A (ja) | 2021-11-18 |
| JPWO2020021097A5 true JPWO2020021097A5 (enExample) | 2022-08-01 |
| JP7478133B2 JP7478133B2 (ja) | 2024-05-02 |
Family
ID=63077813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504186A Active JP7478133B2 (ja) | 2018-07-26 | 2019-07-26 | 腎障害の処置で使用するための化合物 |
| JP2024068208A Pending JP2024096989A (ja) | 2018-07-26 | 2024-04-19 | 腎障害の処置で使用するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068208A Pending JP2024096989A (ja) | 2018-07-26 | 2024-04-19 | 腎障害の処置で使用するための化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200085810A1 (enExample) |
| EP (2) | EP4537901A3 (enExample) |
| JP (2) | JP7478133B2 (enExample) |
| KR (1) | KR102860768B1 (enExample) |
| CN (2) | CN112469442B (enExample) |
| AU (1) | AU2019310919B2 (enExample) |
| CA (1) | CA3104793A1 (enExample) |
| ES (1) | ES3005632T3 (enExample) |
| IL (1) | IL280368B2 (enExample) |
| MX (1) | MX2021000976A (enExample) |
| PL (1) | PL3826679T3 (enExample) |
| TW (1) | TWI891608B (enExample) |
| WO (1) | WO2020021097A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| MXPA06010815A (es) | 2004-03-26 | 2006-12-15 | Hoffmann La Roche | Tetrahidrocarbazoles y derivados de los mismos. |
| EP1756096B1 (en) | 2004-05-03 | 2009-08-12 | F.Hoffmann-La Roche Ag | Indolyl derivatives as liver-x-receptor modulators |
| UA107088C2 (xx) * | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| BR112014005634A2 (pt) | 2011-09-12 | 2017-03-28 | Hoffmann La Roche | hidrazidas de 3-piridina ácido carboxílico como agentes de aumento de colesterol hdl |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| KR20160030206A (ko) * | 2013-07-10 | 2016-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
-
2019
- 2019-07-25 US US16/522,116 patent/US20200085810A1/en not_active Abandoned
- 2019-07-26 CN CN201980048869.4A patent/CN112469442B/zh active Active
- 2019-07-26 CN CN202311697211.0A patent/CN117736141A/zh active Pending
- 2019-07-26 EP EP24213767.7A patent/EP4537901A3/en active Pending
- 2019-07-26 KR KR1020217002388A patent/KR102860768B1/ko active Active
- 2019-07-26 JP JP2021504186A patent/JP7478133B2/ja active Active
- 2019-07-26 IL IL280368A patent/IL280368B2/en unknown
- 2019-07-26 TW TW108126640A patent/TWI891608B/zh active
- 2019-07-26 PL PL19749657.3T patent/PL3826679T3/pl unknown
- 2019-07-26 MX MX2021000976A patent/MX2021000976A/es unknown
- 2019-07-26 AU AU2019310919A patent/AU2019310919B2/en active Active
- 2019-07-26 EP EP19749657.3A patent/EP3826679B1/en active Active
- 2019-07-26 CA CA3104793A patent/CA3104793A1/en active Pending
- 2019-07-26 ES ES19749657T patent/ES3005632T3/es active Active
- 2019-07-26 WO PCT/EP2019/070251 patent/WO2020021097A1/en not_active Ceased
-
2021
- 2021-03-19 US US17/206,955 patent/US20210275514A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,124 patent/US20240325372A1/en active Pending
- 2024-04-19 JP JP2024068208A patent/JP2024096989A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202146021A (zh) | 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合 | |
| US20220339169A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| JP2014508720A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| US12208097B2 (en) | Protein kinase C inhibitors for treatment of uveal melanoma | |
| JP2017505293A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| AU2005282290B2 (en) | Combination of organic compounds | |
| JP2019525948A5 (enExample) | ||
| JP2020520910A5 (enExample) | ||
| JP4774995B2 (ja) | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 | |
| JP2013536206A5 (enExample) | ||
| JPWO2020021097A5 (enExample) | ||
| US20240245682A1 (en) | Alpha-v-beta-8 integrin inhibitors and uses thereof | |
| JPWO2020243135A5 (enExample) | ||
| JPWO2016047799A1 (ja) | 脂質異常症治療剤 | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| JP7644988B2 (ja) | Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物 | |
| JP2023044626A (ja) | 細胞貪食を増加させる方法 | |
| TW202146024A (zh) | 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 | |
| CN117085123A (zh) | 抗PD-L1抗体和c-Met激酶抑制剂的药物组合 | |
| HK40077239A (en) | Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibody |